BCM
AXDX

Bridgeway Capital Management’s Accelerate Diagnostics AXDX Stock Holding History

Bridgeway Capital Management’s Portfolio AXDX Stock Details AXDX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-1,380
Closed -$72K – 1312
2021
Q4 		$72K Hold
1,380
– – ﹤0.01% 1232
2021
Q3 		$80K Buy
+1,380
New +$90K ﹤0.01% 1261
2013
Q4 		– Sell
-1,980
Closed -$266K – 1395
2013
Q3 		$266K Hold
1,980
– – 0.01% 1249
2013
Q2 		$161K Buy
+1,980
New +$147K 0.01% 1307

Other funds holding AXDX

OIM
Oracle Investment Management Greenwich, Connecticut $168M AUM 42.86% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
BC
Birchview Capital Burlington, Vermont $214M AUM 185.33% 1-Year Est. Return
Baird Financial Group
Baird Financial Group Milwaukee, Wisconsin $72.7B AUM 26.4% 1-Year Est. Return
GAM
Griffin Asset Management New York $949M AUM 24.98% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
CC
Cannell & Co New York $3.15B AUM 30.62% 1-Year Est. Return
Axa
Axa Paris, France $91.9M AUM 27.41% 1-Year Est. Return
William Blair & Company
William Blair & Company Chicago, Illinois $38.4B AUM 25.71% 1-Year Est. Return

Bridgeway Capital Management's AXDX Position: Q1 2022 in Review

Bridgeway Capital Management sold out of Accelerate Diagnostics (AXDX) in Q1 2022, closing a stake of 1,380 shares — an estimated $72K sold.

Bridgeway Capital Management first reported a position in AXDX in Q2 2013 and held it in 4 quarters. The position peaked at $266K in Q3 2013. 106 funds tracked by Wall St. Rank hold AXDX as of Q1 2022.

  • Bridgeway Capital Management reported no remaining Accelerate Diagnostics position as of Q1 2022 after selling out during the quarter.
  • Bridgeway Capital Management sold 1,380 Accelerate Diagnostics shares in Q1 2022, an estimated $72K.
  • Bridgeway Capital Management first reported a position in Accelerate Diagnostics in Q2 2013 and held it in 4 quarters.
  • Bridgeway Capital Management's Accelerate Diagnostics position peaked at $266K in Q3 2013.
  • 106 funds tracked by Wall St. Rank held Accelerate Diagnostics as of Q1 2022.

Based on Bridgeway Capital Management's 13F filing for Q1 2022, filed 16 May 2022.